RUA Life Sciences PLC Exercise of Warrants, Issue of Equity & TVR (8311C)

TIDMRUA

RNS Number : 8311C

RUA Life Sciences PLC

21 October 2020

RUA Life Sciences plc

("RUA", the "Company" or the "Group")

Exercise of Warrants

Issue of Equity

and

Total Voting Rights

RUA Life Sciences plc (AIM: RUA.L), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon(TM)), announces that it has received notification from Shore Capital for the exercise of warrants held by Stockdale Securities Limited over 166,667 ordinary shares of 5 pence each in the Company ("Ordinary Shares") at an exercise price of 30 pence per share providing the Company with proceeds of GBP50,000.10.

Application has therefore been made for 166,667 new Ordinary Shares to be admitted to trading on AIM. Admission is expected to occur at 8.00 a.m. on 23 October 2020.

Following Admission, the Company will have 16,353,275 Ordinary Shares in issue and admitted to trading on AIM. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information contact:

RUA Life Sciences

   Bill Brown, Chairman                                 Tel: [phone] 
   David Richmond, CEO                                Tel: [phone] 

Shore Capital

   Tom Griffiths/David Coaten                      Tel: [phone] 

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon(TM) , the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-Eon(TM) , manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
 RUA Medical :      End-to-end contract developer and manufacturer 
                     of medical devices and implantable fabric specialist. 
 RUA Biomaterials   Licensor of Elast-Eon(TM) polymers to the medical 
  :                  device industry. 
 RUA Vascular:      Development of large bore polymer sealed grafts 
                     and soft tissue patches. 
 RUA Structural     Development of tri leaflet polymeric heart valves. 
  Heart : 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEMBBATMTTTBMM

(END) Dow Jones Newswires

October 21, 2020 11:21 ET (15:21 GMT)